The Korean Journal of Urological Oncology 2014;12(2):59-64.
Published online August 30, 2014.
전이성 신장암에 대한 표적 치료의 시대에서 면역치료의 역할
이기수, 김태효
동아대학교 의과대학 비뇨기과학교실
The Role of Immunotherapy in the Era of TKI with Metastatic Renal Cell Carcinoma
Kisoo Lee , Taehyo Kim
Department of Urology, College of Medicine, Dong-A University, Busan, Korea
Correspondence:  Taehyo Kim
Treatment of metastatic renal cell cancer (mRCC) is rapidly evolving since evidence concerning efficacy of novel molecular targeted drugs recently became available. But, Tyrosine kinase inhibitors achieve objective response or disease stabilization in a higher proportion of patients, but neither cure nor significant survival advantage has been shown for these agents. The role of conventional immunotherapy is still supported to the some patients in some medical centers. we will show the currently approved options available for these disease processes, including the newer agents and selected combinatorial approaches under investigation, and we attempt to identify the role of high-dose IL-2 in the context of current clinical practice. This paper provides a critical overview of the current and future role of cytokine-based immunotherapy in mRCC in light of these new developments. (Korean J Urol Oncol 2014;12:59-64)
Key Words: Renal cell carcinoma, Metastasis, Immunotherphy

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email:
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail:

Copyright © The Korean Urological Oncology Society.

Developed in M2PI